Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria

Lachapelle, Jean‐Marie; Decroix, J.; Henrijean, A; Roquet-Gravy, P P; Swerdt, A De; Boonen, H; Lécuyer, Manon; Suys, E.; Speelman, G.; Vastesaeger, Nathan

doi:10.1111/j.1468-3083.2006.01429.x

Cited by 26 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levocetirizine, a selective H1 antihistamine, controls seasonal allergic rhinitis symptoms in children (34). Use of sedating H1R blockers was also associated with a decreased risk of developing multiple sclerosis (35) and improved the quality of life of patients with chronic idiopathic urticaria (36), suggesting a possible beneficial effect of antihistamines on the onset of some autoimmune diseases. Increased histamine in plasma and tissues is associated with disease severity in human infections with P. falciparum and in animal models of malaria (6–8, 22).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease

Beghdadi

Porcherie

Schneider

et al. 2008

The Journal of Experimental Medicine

View full text Add to dashboard Cite

From the inoculation of Plasmodium sporozoites via Anopheles mosquito bites to the development of blood-stage parasites, a hallmark of the host response is an inflammatory reaction characterized by elevated histamine levels in the serum and tissues. Given the proinflammatory and immunosuppressive activities associated with histamine, we postulated that this vasoactive amine participates in malaria pathogenesis. Combined genetic and pharmacologic approaches demonstrated that histamine binding to H1R and H2R but not H3R and H4R increases the susceptibility of mice to infection with Plasmodium. To further understand the role of histamine in malaria pathogenesis, we used histidine decarboxylase–deficient (HDC−/−) mice, which are free of histamine. HDC−/− mice were highly resistant to severe malaria whether infected by mosquito bites or via injection of infected erythrocytes. HDC−/− mice displayed resistance to two lethal strains: Plasmodium berghei (Pb) ANKA, which triggers cerebral malaria (CM), and Pb NK65, which causes death without neurological symptoms. The resistance of HDC−/− mice to CM was associated with preserved blood–brain barrier integrity, the absence of infected erythrocyte aggregation in the brain vessels, and a lack of sequestration of CD4 and CD8 T cells. We demonstrate that histamine-mediated signaling contributes to malaria pathogenesis. Understanding the basis for these biological effects of histamine during infection may lead to novel therapeutic strategies to alleviate the severity of malaria.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease

Beghdadi

Porcherie

Schneider

et al. 2008

The Journal of Experimental Medicine

View full text Add to dashboard Cite

show abstract

“…Second-generation antihistamines are the recommended first-line therapy for chronic idiopathic urticaria [6]. Desloratadine, a newer, nonsedating, second-generation antihistamine, is effective, safe, and provides rapid onset of action and long duration of symptom relief while improving QoL [1,21,22]. …”

Section: Introductionmentioning

confidence: 99%

Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice‐based Study

Kim

Lynde

2008

Archives of Drug Info

View full text Add to dashboard Cite

BackgroundControlled trials have demonstrated the efficacy of antihistamines in the treatment of chronic idiopathic urticaria. Second-generation antihistamines are recommended as first-line therapy for chronic idiopathic urticaria. The purpose of this study was to determine the effect of desloratadine, a newer, nonsedating, second-generation antihistamine, on symptoms of chronic idiopathic urticaria, disease severity, and quality of life (QoL).MethodsIn an open-label, observational, multicenter study, 348 subjects with chronic idiopathic urticaria were given 5 mg of desloratadine once daily for 2 weeks. Outcome measures included change from baseline at Day 14 using the Aerius Quality of Life Questionnaire (AEQLQ); change from baseline in pruritus score, number and maximum size of hives, sleep quality, and activity impairment; and subjects' response to therapy.ResultsDesloratadine significantly decreased subjects' overall condition and symptom scores from baseline to Day 14 (2.19 ± [SD] 0.66 and 1.14 ± 0.89, respectively; P < 0.0001). Desloratadine treatment significantly improved all 10 AEQLQ domain scores from baseline to Day 7 and Day 14 (P < 0.0001). Sleep disturbance scores decreased 40% from baseline to Day 7 (1.42 ± 1.03 to 0.85 ± 0.89, respectively), and interference with daily outdoor activity scores showed a 41% decrease from baseline to Day 7 (1.11 ± 0.98 to 0.66 ± 0.90) (P < 0.0001 for both). There were significant reductions in itching, size of hives, and hive score at both Days 7 and 14. Treatment resulted in moderate, marked, or complete relief of symptoms in 76.2% of subjects. Desloratadine was well tolerated, with no adverse events reported.ConclusionIn an open-label, observational study, desloratadine 5 mg once daily significantly decreased symptoms of chronic idiopathic urticaria and improved subject QoL.

show abstract

“…Safe and well tolerated, they represent a major advance in the management of urticaria. Levocetirazine is the active enantiomer of the racemate cetirizine, fexofenadine the active metabolite of terfinadine, and desloratadine an active metabolite of loratadine [66]. Levocetirizine is from the latest generation approved for CU and also demonstrated a broad anti-inflammatory effect in patients with CU [18,59].…”

Section: First Line Of Treatmentmentioning

confidence: 99%

Current advances in the management of urticaria

Khalaf

Tan

2008

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Urticaria is a relatively common autoimmune/autoreactive skin disorder that may severely impair quality of life. Although rarely life-threatening, widespread urticaria and its associated angioedema can be an extremely disabling and difficult-to-treat condition. Patients may suffer symptoms such as pruritus and disfigurement due to wheals for years or decades. Urticaria is caused by cutaneous mast-cell degranulation attributed to immunological, non-immunological, and idiopathic causes. The last decade has seen some notable advances in the understanding of the etiology and pathogenesis of common forms of urticaria and their management. Furthermore, the wide diversity in urticaria subtypes has been identified and this reflects a partial understanding of the causes or factors that trigger it as well as the molecular and cellular mechanisms that are involved in its physiopathology. In addition, new instruments for diagnosing urticaria variants and for assessing quality of life in urticaria patients have been developed. Finally, several clinical trials have demonstrated the efficacy of novel treatment approaches for urticaria, while other therapeutic concepts are under development. The objective of this article was to review the literature to be able to offer the readers comprehensive and updated information on the basic etiological and physiopathological mechanisms and to make special emphasis on the current management of urticaria, thus promoting continuous medical education.

show abstract

Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria

Abstract: Desloratadine significantly improves the quality of life of patients with chronic idiopathic urticaria as reflected by the dermatology life quality index (DLQI).

Cited by 26 publications

References 13 publications

Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease

Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease

Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice‐based Study

Current advances in the management of urticaria

Contact Info

Product

Resources

About